How to Help Your Patients Save Money on Veltassa: A Provider's Guide to Savings Programs

Veltassa (patiromer) is a clinically important medication for managing chronic hyperkalemia — but with a retail price of approximately $1,200–$1,500 per month for a standard dose and no generic currently available, affordability is a real barrier to adherence. As the prescribing clinician, understanding the savings landscape and proactively connecting patients to the right programs can be the difference between a patient who takes their medication and one who simply can't afford to. This guide gives you a complete overview of savings programs for Veltassa and practical steps your care team can take.

Understanding the Cost Landscape

Before diving into programs, it's important to understand why Veltassa is expensive and why cost barriers persist:

Brand-only: There is no FDA-approved generic patiromer. Patent expiration is expected around 2028. Until then, patients pay brand-drug prices.

Specialty tier formulary placement: Most insurance plans classify Veltassa as a specialty or Tier 3/4 drug, which means higher copays and coinsurance requirements even with coverage.

Prior authorization: Most plans require PA, adding administrative burden and delay that can discourage patients from pursuing therapy.

Medicare gap: A significant portion of Veltassa patients are Medicare beneficiaries who are ineligible for manufacturer co-pay programs. This leaves a gap that requires creative problem-solving.

Program 1: Vifor Pharma Co-Pay Savings Program (Commercially Insured Patients)

This is the most impactful program for your commercially insured patients:

Eligible patients may pay as little as $0 per month for up to 12 months. Renewal is required.

Must have commercial (private or employer-sponsored) insurance; government programs (Medicare, Medicaid, TRICARE, VA) are excluded

Annual maximum limits apply; co-pay program is not insurance

Enrollment: through Veltassa Konnect (1-844-835-8277) or at veltassa.com

Practical tip: Have your medical assistant or care coordinator enroll commercially insured patients in the co-pay program at the time of prescribing. This prevents sticker shock at the pharmacy and dramatically reduces the likelihood of non-fill.

Program 2: Veltassa Konnect — Free Starter Supply During Benefits Verification

Veltassa Konnect provides a critical bridge for newly prescribed patients:

A free 15-day supply is provided directly to the patient while insurance coverage is being determined

If the benefits verification process takes longer than expected, a second 15-day supply is available

Eliminates the gap in therapy that commonly occurs while PA is being processed

This starter supply program is particularly valuable for patients with acute hyperkalemia who need to begin therapy immediately. Contact Veltassa Konnect at 1-844-835-8277.

Program 3: Free Drug Program for Uninsured Patients

Patients without any insurance coverage who meet financial eligibility criteria may receive Veltassa at no cost through Vifor Pharma's patient assistance program. Direct patients to call 1-844-870-7597 or have your office contact Veltassa Konnect to initiate enrollment. Financial documentation (income verification) is typically required.

Program 4: PAN Foundation — For Medicare and Other Patients with Financial Need

The Patient Access Network (PAN) Foundation is one of the few resources available for Medicare Part D beneficiaries who cannot afford their Veltassa copays. Since the manufacturer's co-pay program explicitly excludes Medicare patients, PAN Foundation fills a critical gap:

Eligibility based on income (up to 400–500% of Federal Poverty Level, depending on program year)

Provides copay assistance for Medicare beneficiaries and others with insurance but financial hardship

Contact: panfoundation.org or 1-866-316-7263

Practical tip: For high-volume nephrology or cardiology practices, consider designating a staff member to check PAN Foundation eligibility for Medicare patients when prescribing Veltassa. The application is online and straightforward.

Program 5: 90-Day Mail-Order Supply

For patients on long-term Veltassa therapy, switching to 90-day mail-order supply through their insurance plan's preferred specialty pharmacy typically reduces the per-packet cost. Medicare Part D plans in particular often offer lower cost-sharing for 90-day supplies through their mail-order channel. Remind patients to contact their plan to set this up — it requires a new prescription written for a 90-day supply.

Helping Patients Navigate Prior Authorization

PA denials are a major contributor to non-adherence. Strong PA submissions can minimize this friction:

Include dated serum potassium levels (typically > 5.0 mEq/L threshold required)

Document primary diagnosis: CKD stage, heart failure, diabetic nephropathy

Document RAAS inhibitor therapy and rationale for continuation (renal protection, heart failure treatment)

Include clinical rationale for Veltassa over SPS (step therapy requirements), e.g., better tolerability, lower GI risk, or sodium-free formula for HF patients

Use Veltassa Konnect's PA support service — they can help prepare and submit the request

Helping Patients Find the Medication

Affordability and availability go hand in hand. A patient who can afford Veltassa but can't find it stocked near them still can't take it. Recommend medfinder for providers to your patients — it calls local pharmacies to check which have Veltassa in stock and texts results to the patient. This eliminates a major source of access frustration and helps ensure therapy continuity.

Provider Affordability Checklist for Veltassa

Enroll commercially insured patients in Vifor Co-pay Program at time of prescribing (target: $0/month)

Request free 15-day starter supply via Veltassa Konnect for all new starts

Screen Medicare patients for PAN Foundation eligibility (panfoundation.org, 1-866-316-7263)

Refer uninsured patients to free drug program (1-844-870-7597)

Submit strong PA with complete clinical documentation; use Konnect PA support

Recommend medfinder to help patients locate stocking pharmacies

Switch long-term patients to 90-day mail-order supply to reduce per-dose cost